I am not capable of viewing this company objectively as I have held for too long. I meant to say CRIS presentation at AACR shows promise that ph1 results will be favorable for solid tumors. Regarding Ph2 trial, by ASH in December we will know whether 907 getting same results as in Ph1. If they are the same, then drug will have to be taken seriously.
How many times have they done that???????????????????????????????????
these are items for those who play the stock for pennies up and down. Not good for long term investors who invest in progress. Ali and team suck. VOTE NO TO ALL THEIR ITEMS IF YOU OWN ANY STOCK.
Tar with all due respect if the idiots are still talking about preclinical eficacy models now............to convince the community it is a shame on Ali and his crew. I understand they need to survive, raise a family and somehow find the resource to live a comfortable life but there is also a thing called "sincerity, honesty, commitment and hard work". I hold a ton of this stock but if they keep repeating the same old story over and over and over again.....ph1 results for 3 years now. The same thing over and over again. Now to distract us they have introduced the "exciting" check point blockers IRAK and PDL1.
Please vote NO to the directors...............everybody who owns any bit of CRIS vote NO TO ALL. Atleast they will get a message to work harder and get stuff moving ahead.
Curis researchers will present data for its proprietary targeted cancer drug candidate, CUDC-427, an oral antagonist of inhibitor of apoptosis or IAP proteins. Curis' collaborator, Aurigene will present data from their interleukin-1 receptor association kinase-4, or IRAK-4, inhibitor program.
Sentiment: Strong Buy
Should be informative, 907 making progress on the tumor front:
"Significant antitumor effects have been consistently observed in MYC-driven DLBCL xenograft and genetically engineered mouse models exposed to CUDC907. In particular, certain MYC translocation (Daudi), double-hit (concurrent MYC and BLC2 translocation, WSUDLCL2 and DOHH2), double-expresser (expression of MYC and BCL2 proteins, U2932) xenograft models, and the Eµ-Myc transgenic mouse model achieve tumor growth inhibition of 100%, 69%, 56%, 97% and 72%, respectively.
These findings raise the possibility that hematologic and solid tumors driven by aberrant overexpression of MYC family genes (e.g., MYC-altered DLBCL and NMC) might be more responsive to simultaneous HDAC and PI3K inhibition with CUDC-907 than they are to single-target therapy. Clinical Phase 1 studies are currently testing CUDC-907 in patients with relapsed/refractory (R/R) DLBCL and advanced MYC-aberrant solid tumors. Preliminary data are encouraging and support the planned Phase 2 study in R/R MYC-altered DLBCL, as well as further testing in other MYC-driven malignancies."
It's actually good if they don't have time to present. It means they are actually to busy with clinical trials have enough cash and don't need to prostitute for funding
looks like Curis was a no show; not confident they are presenting at AACR next week either; looks lie we have until ASH in December to wait for any definitive news on 907.
Present and say what tar??
All Ali team has to say has been said gazillion times already. Maybe he might finally give out the names and addresses of the patients that had the objective response lol
Honestly, I understand it takes time for these things but man this is incredibly long time they had playing with one piece of data.
Curis expects that it will make presentations at the following investor and scientific conferences through April 2016:
Cowen and Company 36th Annual Health Care Conference on March 7-9 in Boston, MA
ROTH Capital Growth Conference on March 13-16 in Los Angeles, CA
Jefferies 2016 Immuno-Oncology Summit on April 7-8 in Boston, MA
American Association for Cancer Research (AACR) Annual Meeting on April 16-20 in New Orleans, LA
Recruiting at Oklahoma and Kentucky cancer treatment centers: regarding monotherapy trial, if we see positive results as good as or better than Ph1 trial, then Cris onto something as it appears there is an unmet need for treatment of MYC altered refractory/relapsed DLBCL patients. I wonder if CRIS has begun dosing. I am assuming it has not since recruiting is ongoing and that once completed it can begin dosing.
United States, Kentucky
Norton Cancer Institute Recruiting
Louisville, Kentucky, United States, 40207
United States, Oklahoma
Oklahoma Cancer Specialists and Research Institute, LLC Recruiting
Tulsa, Oklahoma, United States, 74146